Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, Cisplatin, and Radiotherapy in Uterine Cervical Cancer
NCT00421096Phase 2Terminated
- Sponsor
- Centre Oscar Lambret
- Start
- May 2005
- Primary completion
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine in Cervical Cancer (CC), sponsored by Centre Oscar Lambret. Primary endpoint: Progression-free survival at 3 years. Started May 2005; status: terminated.
02
Drugs
gemcitabine
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT00421096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00421096.